Vesicore 5 mg (Solifenacin Succinate)

Adult dose

The usual recommended dose for adults (including older adults) is 5mg once daily. If needed, the dose may be increased to a maximum of 10mg once daily. This medicine may be taken with or without food and should be swallowed whole with water. No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance>30ml/min). Use with caution in patients with severe renal impairment (creatinine clearance≤30ml/min), and do not exceed 5mg once daily. No dose adjustment is necessary in patients with mild hepatic impairment. Use with caution in patients with moderate hepatic impairment (Child-Pugh class B), and do not exceed 5mg once daily. For patients receiving ketoconazole or other strong CYP3A4 inhibitors (e.g., ritonavir, nelfinavir, itraconazole), limit the maximum daily dose to 5mg.

This medication should not be used in patients with urinary retention symptoms or serious gastrointestinal issues such as toxic megacolon. Additionally, patients with myasthenia gravis, narrow-angle glaucoma, allergies to this medication or its components, those undergoing hemodialysis, or those with severe liver or kidney dysfunction should also avoid this medication. It is also not suitable for patients with genetic lactose intolerance. Caution is advised for patients at risk of urinary retention or those with gastrointestinal obstructive diseases or risk of decreased gastrointestinal motility. Patients with moderate to severe impairment of kidney or liver function should have their dosage limited, and careful monitoring is necessary when used with certain strong medications. Side effects such as dry mouth, constipation, blurred vision, urinary retention, and dry eyes may occur, and these may be more frequent with higher doses. Serious side effects, though rare, include bowel obstruction, angioedema, and anaphylactic reactions; should symptoms appear, the use of the drug must be suspended immediately, and medical assistance sought. Caution is also advised when driving or operating machinery, as drowsiness or blurred vision may occur. Co-administration with other anticholinergic drugs may enhance effects or increase side effects; caution is warranted during combined use. Furthermore, this drug is metabolized by specific liver enzymes, so dosage adjustment is necessary when taken with strong CYP3A4 inhibitors. The safety for pregnant women has not been established; therefore, it should be used with caution during pregnancy. During breastfeeding, it is best to avoid this medication due to potential harm to the newborn through breast milk. The safety and efficacy for children have not been confirmed, so it should not be used in pediatric patients. In cases of overdose, central nervous system symptoms, cardiac problems, and urinary retention may occur, necessitating immediate medical treatment. Prior to taking this medication, it is essential to consult with healthcare professionals regarding existing conditions and medications for safe usage.

• Dry mouth
• constipation
• blurred vision
• urinary retention
• dry eyes
• fecal impaction
• colonic obstruction
• intestinal obstruction
• angioedema
• nausea

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. It is best kept at room temperature between 1 and 30 degrees Celsius.

Appearance

Bright yellow round film-coated tablet

Package unit

100 tablets (10 tablets/PTP packaging x 10), 30 tablets/bottle, 100 tablets/bottle